CFD merupakan instrumen yang rumit dan memiliki risiko tinggi kehilangan uang secara cepat karena adanya pengaruh leverage. 84% akun investor ritel mengalami kerugian saat melakukan kegiatan perdagangan CFD dengan penyedia ini. Anda harus mempertimbangkan apakah Anda memahami cara kerja CFD dan apakah Anda mampu menerima risiko tinggi kehilangan uang.

Perdagangan Lineage Cell Therapeutics, Inc. - LCTX CFD

1.25
4.58%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.09
Biaya inap posisi Long

Long position overnight fee


Margin. Your investment $1,000.00
Biaya Overnight -0.025457 %
Charges from borrowed part ($-1.02)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Kunjungi platform
-0.025457%
Biaya inap posisi short

Short position overnight fee


Margin. Your investment $1,000.00
Biaya Overnight 0.003235 %
Charges from borrowed part ($0.13)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Kunjungi platform
0.003235%
Waktu biaya inap 21:00 (UTC)
Kuantitas min. yang diperdagangkan 1
Mata uang USD
Margin 20%
Bursa efek United States of America
Komisi perdagangan 0%

*Information provided by Capital.com

Lineage Cell Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

Key Stats
Prev. Close* 1.31
Open* 1.32
1-Year Change* -10.81%
Day's Range* 1.25 - 1.33
52 wk Range 1.02-1.79
Average Volume (10 days) 413.10K
Average Volume (3 months) 7.57M
Market Cap 229.74M
P/E Ratio -100.00K
Shares Outstanding 170.17M
Revenue 11.85M
EPS -0.14
Dividend (Yield %) N/A
Beta 1.69
Next Earnings Date Aug 9, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jun 7, 2023 1.31 -0.03 -2.24% 1.34 1.35 1.31
Jun 6, 2023 1.32 0.06 4.76% 1.26 1.36 1.26
Jun 5, 2023 1.25 -0.01 -0.79% 1.26 1.29 1.22
Jun 2, 2023 1.29 0.04 3.20% 1.25 1.31 1.24
Jun 1, 2023 1.25 0.02 1.63% 1.23 1.27 1.22
May 31, 2023 1.24 0.03 2.48% 1.21 1.27 1.21
May 30, 2023 1.22 -0.06 -4.69% 1.28 1.28 1.22
May 26, 2023 1.26 0.01 0.80% 1.25 1.27 1.25
May 25, 2023 1.25 -0.02 -1.57% 1.27 1.29 1.25
May 24, 2023 1.29 0.01 0.78% 1.28 1.32 1.28
May 23, 2023 1.29 -0.04 -3.01% 1.33 1.35 1.29
May 22, 2023 1.32 -0.03 -2.22% 1.35 1.36 1.32
May 19, 2023 1.33 0.01 0.76% 1.32 1.36 1.32
May 18, 2023 1.31 -0.02 -1.50% 1.33 1.36 1.31
May 17, 2023 1.34 0.00 0.00% 1.34 1.36 1.34
May 16, 2023 1.32 0.00 0.00% 1.32 1.36 1.31
May 15, 2023 1.36 0.03 2.26% 1.33 1.37 1.32
May 12, 2023 1.35 -0.04 -2.88% 1.39 1.41 1.35
May 11, 2023 1.39 0.00 0.00% 1.39 1.41 1.37
May 10, 2023 1.40 -0.02 -1.41% 1.42 1.46 1.39

Lineage Cell Therapeutics, Inc. Events

Time (UTC) Country Event
Wednesday, August 9, 2023

Time (UTC)

10:59

Country

US

Event

Q2 2023 Lineage Cell Therapeutics Inc Earnings Release
Q2 2023 Lineage Cell Therapeutics Inc Earnings Release

Forecast

-

Previous

-
Wednesday, November 8, 2023

Time (UTC)

10:59

Country

US

Event

Q3 2023 Lineage Cell Therapeutics Inc Earnings Release
Q3 2023 Lineage Cell Therapeutics Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 14.703 4.341 1.826 3.515 4.988
Revenue 14.703 4.341 1.826 3.515 4.988
Cost of Revenue, Total 0.728 1.426 0.385 0.412 0.302
Gross Profit 13.975 2.915 1.441 3.103 4.686
Total Operating Expense 37.223 53.029 28.273 42.391 -31.728
Selling/General/Admin. Expenses, Total 22.508 18.212 15.571 24.031 24.726
Research & Development 13.887 33.714 11.117 15.948 18.755
Unusual Expense (Income) 0 -0.523 0 -77.711
Operating Income -22.52 -48.688 -26.447 -38.876 36.716
Interest Income (Expense), Net Non-Operating -1.365 3.727 1.817 16.499 -82.531
Other, Net -1.927 1.691 2.706 3.143 -1.315
Net Income Before Taxes -25.812 -43.27 -21.924 -19.234 -47.13
Net Income After Taxes -26.353 -43.27 -20.685 -11.827 -46.784
Minority Interest 0.08 0.251 0.036 0.118 0.794
Net Income Before Extra. Items -26.273 -43.019 -20.649 -11.709 -45.99
Net Income -26.273 -43.019 -20.649 -11.709 -45.99
Total Adjustments to Net Income
Income Available to Common Excl. Extra. Items -26.273 -43.019 -20.649 -11.709 -45.99
Income Available to Common Incl. Extra. Items -26.273 -43.019 -20.649 -11.709 -45.99
Dilution Adjustment
Diluted Net Income -26.273 -43.019 -20.649 -11.709 -45.99
Diluted Weighted Average Shares 169.792 164.502 150.044 145.533 126.903
Diluted EPS Excluding Extraordinary Items -0.15474 -0.26151 -0.13762 -0.08046 -0.3624
Diluted Normalized EPS -0.15474 -0.26469 -0.13762 -0.08046 -0.75823
Depreciation / Amortization 0.1 0.2 1.2 2 2.2
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total revenue 2.386 1.915 2.998 4.553 5.237
Revenue 2.386 1.915 2.998 4.553 5.237
Cost of Revenue, Total 0.119 0.102 0.235 0.215 0.176
Gross Profit 2.267 1.813 2.763 4.338 5.061
Total Operating Expense 9.028 8.554 8.249 8.787 11.633
Selling/General/Admin. Expenses, Total 4.724 4.348 4.422 5.27 8.469
Research & Development 4.185 4.104 3.592 3.302 2.988
Depreciation / Amortization
Operating Income -6.642 -6.639 -5.251 -4.234 -6.396
Interest Income (Expense), Net Non-Operating 0.45 -0.123 0.151 -0.658 -0.734
Other, Net -0.015 0.4 -0.475 -1.89 0.037
Net Income Before Taxes -6.207 -6.362 -5.575 -6.782 -7.093
Net Income After Taxes -4.404 -6.362 -6.116 -6.782 -7.093
Minority Interest 0.032 0.008 0.047 0.019 0.006
Net Income Before Extra. Items -4.372 -6.354 -6.069 -6.763 -7.087
Net Income -4.372 -6.354 -6.069 -6.763 -7.087
Income Available to Common Excl. Extra. Items -4.372 -6.354 -6.069 -6.763 -7.087
Income Available to Common Incl. Extra. Items -4.372 -6.354 -6.069 -6.763 -7.087
Diluted Net Income -4.372 -6.354 -6.069 -6.763 -7.087
Diluted Weighted Average Shares 170.127 170.002 169.786 169.731 169.647
Diluted EPS Excluding Extraordinary Items -0.0257 -0.03738 -0.03574 -0.03985 -0.04177
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.0257 -0.03738 -0.03574 -0.03985 -0.04177
Unusual Expense (Income) 0 0 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 60 111.549 43.999 57.519 36.358
Cash and Short Term Investments 57.875 58.358 41.562 30.716 30.741
Cash & Equivalents 11.355 55.742 32.585 9.497 23.587
Short Term Investments 46.52 2.616 8.977 21.219 7.154
Total Receivables, Net 0.297 50.84 0.004 23.94 3.719
Accounts Receivable - Trade, Net 0.297 50.84 0.004 0.044 0.891
Prepaid Expenses 1.828 2.351 2.433 2.863 1.898
Total Assets 123.664 174.545 107.949 125.478 101.66
Property/Plant/Equipment, Total - Net 5.673 4.872 5.63 8.175 5.835
Property/Plant/Equipment, Total - Gross 11.523 10.174 9.945 12.766 9.02
Accumulated Depreciation, Total -5.85 -5.302 -4.315 -4.591 -3.185
Intangibles, Net 46.692 46.822 47.032 48.248 3.125
Long Term Investments 0 33.733
Other Long Term Assets, Total 0.627 0.63 0.616 0.864 0.505
Total Current Liabilities 18.981 47.116 7.769 6.494 6.812
Accounts Payable 2.393 3.543 2.611 2.427 2.359
Accrued Expenses 7.131 25.049 4.416 3.985 4.332
Notes Payable/Short Term Debt 0 0 0.523 0 0
Current Port. of LT Debt/Capital Leases 0.036 0.03 0.016 0.033 0.07
Other Current Liabilities, Total 9.421 18.494 0.203 0.049 0.051
Total Liabilities 50.325 82.324 11.75 12.519 7.82
Total Long Term Debt 0.084 0.03 0.026 0.077 1.958
Long Term Debt 0
Capital Lease Obligations 0.084 0.03 0.026 0.077 1.958
Minority Interest -1.403 -1.323 -1.072 -1.712 -1.594
Other Liabilities, Total 30.587 34.425 2.951 4.345 0.644
Total Equity 73.339 92.221 96.199 112.959 93.84
Preferred Stock - Non Redeemable, Net 0 0 0
Common Stock 440.28 434.529 393.944 387.062 354.27
Retained Earnings (Accumulated Deficit) -363.37 -337.097 -294.078 -273.422 -261.856
Treasury Stock - Common
Other Equity, Total -3.571 -5.211 -3.667 -0.681 1.426
Total Liabilities & Shareholders’ Equity 123.664 174.545 107.949 125.478 101.66
Total Common Shares Outstanding 170.093 169.477 153.096 149.804 127.136
Note Receivable - Long Term 0 22.104
Goodwill, Net 10.672 10.672 10.672 10.672
Deferred Income Tax 2.076 2.076 2.076 3.315
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 49.655 60 68.509 74.026 81.872
Cash and Short Term Investments 46.814 57.875 66.355 72.03 79.944
Cash & Equivalents 15.451 11.355 24.752 70.857 78.062
Short Term Investments 31.363 46.52 41.603 1.173 1.882
Total Receivables, Net 0.203 0.297 0.434 0.707 0.515
Accounts Receivable - Trade, Net 0.203 0.297 0.434 0.707 0.515
Prepaid Expenses 2.638 1.828 1.72 1.289 1.413
Total Assets 113.205 123.664 131.148 135.922 144.52
Property/Plant/Equipment, Total - Net 5.584 5.673 4.652 3.869 4.548
Property/Plant/Equipment, Total - Gross 11.694 11.523 10.464 9.414 10.135
Accumulated Depreciation, Total -6.11 -5.85 -5.812 -5.545 -5.587
Goodwill, Net 10.672 10.672 10.672 10.672 10.672
Intangibles, Net 46.659 46.692 46.724 46.757 46.789
Other Long Term Assets, Total 0.635 0.627 0.591 0.598 0.639
Total Current Liabilities 17.225 18.981 22.739 25.091 24.593
Accounts Payable 3.001 2.393 2.865 2.589 2.956
Accrued Expenses 3.126 7.131 7.46 6.678 6.642
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.051 0.036 0.025 0.029 0.031
Other Current Liabilities, Total 11.047 9.421 12.389 15.795 14.964
Total Liabilities 42.755 50.325 52.2 53.075 57.973
Total Long Term Debt 0.133 0.084 0.016 0.019 0.026
Capital Lease Obligations 0.133 0.084 0.016 0.019 0.026
Deferred Income Tax 0.273 2.076 2.076 2.076 2.076
Minority Interest -1.435 -1.403 -1.395 -1.348 -1.329
Other Liabilities, Total 26.559 30.587 28.764 27.237 32.607
Total Equity 70.45 73.339 78.948 82.847 86.547
Common Stock 441.299 440.28 439.148 437.151 435.818
Retained Earnings (Accumulated Deficit) -367.742 -363.37 -357.016 -350.947 -344.184
Other Equity, Total -3.107 -3.571 -3.184 -3.357 -5.087
Total Liabilities & Shareholders’ Equity 113.205 123.664 131.148 135.922 144.52
Total Common Shares Outstanding 170.174 170.093 169.886 169.748 169.727
Preferred Stock - Non Redeemable, Net 0 0 0 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -26.273 -43.019 -20.649 -11.709 -45.99
Cash From Operating Activities 1.059 -23.561 -19.753 -31.947 -30.882
Cash From Operating Activities 0.582 0.663 0.895 1.131 1.081
Amortization 0.145 0.21 1.216 1.998 2.192
Deferred Taxes
Non-Cash Items 7.901 -2.511 -2.516 -21.464 11.197
Cash Interest Paid 0.013 0.013 0.02 0.028 0.155
Changes in Working Capital 18.704 21.096 1.301 -1.903 0.638
Cash From Investing Activities -46.159 9.745 13.038 16.957 11.816
Capital Expenditures -0.413 -0.354 -0.064 -0.44 -3.287
Other Investing Cash Flow Items, Total -45.746 10.099 13.102 17.397 15.103
Cash From Financing Activities 1.632 36.93 29.865 0.617 5.774
Financing Cash Flow Items -0.123 -1.155 -0.383 0.654 0.161
Issuance (Retirement) of Stock, Net 1.787 38.105 5.127 0.063 5.962
Issuance (Retirement) of Debt, Net -0.032 -0.02 25.121 -0.1 -0.349
Foreign Exchange Effects -0.873 -0.02 -0.063 0.07 0.006
Net Change in Cash -44.341 23.094 23.087 -14.303 -13.286
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -4.372 -26.273 -19.919 -13.85 -7.087
Cash From Operating Activities -11.242 1.059 9.362 14.842 21.904
Cash From Operating Activities 0.138 0.582 0.441 0.296 0.15
Amortization 0.033 0.145 0.113 0.065 0.032
Non-Cash Items 1.098 7.901 7.168 5.861 1.685
Cash Interest Paid 0.002 0.013 0.013 0.009 0.005
Changes in Working Capital -8.139 18.704 21.559 22.47 27.124
Cash From Investing Activities 15.426 -46.159 -41.057 -0.143 -0.046
Capital Expenditures -0.188 -0.413 -0.429 -0.143 -0.046
Other Investing Cash Flow Items, Total 15.614 -45.746 -40.628 0 0
Cash From Financing Activities 0.001 1.632 1.51 0.546 0.513
Financing Cash Flow Items -0.037 -0.123 -0.112 -0.074 -0.008
Issuance (Retirement) of Stock, Net 0.051 1.787 1.645 0.635 0.529
Foreign Exchange Effects -0.1 -0.873 -0.795 -0.161 -0.042
Net Change in Cash 4.085 -44.341 -30.98 15.084 22.329
Deferred Taxes 0 0
Issuance (Retirement) of Debt, Net -0.013 -0.032 -0.023 -0.015 -0.008
Cash Taxes Paid 1.803
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Broadwood Capital, Inc. Hedge Fund 20.5293 34935485 0 2023-04-17 LOW
Kingsley (Alfred D) Individual Investor 4.0249 6849242 0 2023-04-17 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.8225 6504938 397884 2023-03-31 LOW
Defender Capital LLC Investment Advisor 3.0181 5136085 42550 2023-03-31 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 2.1625 3679968 -74234 2023-03-31 LOW
Laurion Capital Management LP Hedge Fund 1.3974 2377940 0 2023-03-31 HIGH
Prescott General Partners LLC Hedge Fund 1.0882 1851851 0 2023-03-31 LOW
Raffles Capital Management, LLC Hedge Fund 0.9032 1536946 0 2023-03-31 LOW
BofA Global Research (US) Research Firm 0.8484 1443779 1442750 2023-03-31 LOW
Millennium Management LLC Hedge Fund 0.8239 1402123 1003084 2023-03-31 HIGH
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.7533 1282000 17591 2023-03-31 LOW
JPMorgan Asset Management U.K. Limited Investment Advisor/Hedge Fund 0.5644 960512 0 2023-03-31 LOW
Susquehanna International Group, LLP Investment Advisor 0.4797 816387 642768 2023-03-31 HIGH
Bridgeway Capital Management, LLC Investment Advisor 0.4594 781766 0 2023-03-31
Jane Street Capital, L.L.C. Research Firm 0.3505 596444 455199 2023-03-31 HIGH
Citi Investment Research (US) Research Firm 0.272 462884 -14290 2023-03-31 MED
State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.2571 437496 0 2023-03-31 LOW
MAI Capital Management, LLC Investment Advisor/Hedge Fund 0.2498 425115 -31702 2023-03-31 LOW
ETF Managers Group, LLC Investment Advisor 0.1872 318596 -35395 2023-03-31 MED
Morgan Stanley & Co. LLC Research Firm 0.1703 289882 169284 2023-03-31 MED

Mengapa memilih Capital.com? Biarlah angka kami yang berbicara.

Capital.com Group

535K+

Trader

87K+

Klien aktif per bulan

$113M+

Volume investasi per bulan

$64M+

Penarikan tiap bulan

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long
Industry: Biotechnology & Medical Research (NEC)

2173 Salk Ave Ste 200
CARLSBAD
CALIFORNIA 92008-7354
US

Income Statement

  • Annual
  • Quarterly

People also watch

XRP/USD

0.53 Price
-0.140% 1D Chg, %
Biaya inap posisi Long -0.0753%
Biaya inap posisi short 0.0069%
Waktu biaya inap 21:00 (UTC)
Spread 0.00395

US100

14,473.70 Price
+1.280% 1D Chg, %
Biaya inap posisi Long -0.0255%
Biaya inap posisi short 0.0032%
Waktu biaya inap 21:00 (UTC)
Spread 1.8

Gold

1,965.31 Price
+1.310% 1D Chg, %
Biaya inap posisi Long -0.0185%
Biaya inap posisi short 0.0103%
Waktu biaya inap 21:00 (UTC)
Spread 0.30

BTC/USD

26,507.30 Price
+0.430% 1D Chg, %
Biaya inap posisi Long -0.0616%
Biaya inap posisi short 0.0137%
Waktu biaya inap 21:00 (UTC)
Spread 60.00

Masih mencari broker yang bisa Anda percayai?

Bergabung dengan 535.000+ trader di seluruh dunia yang telah memilih trading bersama Capital.com

1. Buat & verifikasi akun Anda 2. Lakukan deposit 3. Temukan trading Anda